Pharmaceutical stocks are performing well this year, with the iShares U.S. Pharmaceuticals ETF up almost 29% year to date. AbbVie stands out with strong quarterly results, exceeding sales and earnings forecasts. Top-performing drugs like Skyrizi and Rinvoq are driving revenue growth, with management expecting big numbers by 2027.

Consider this before buying AbbVie stock: The Motley Fool Stock Advisor team has identified the 10 best stocks to buy now, and AbbVie isn’t one of them. Past recommendations like Netflix and Nvidia have yielded significant returns. Stock Advisor boasts a total average return of 991%, outperforming the S&P 500.

Read more at Yahoo Finance: The Pharmaceutical Sector Is Surging. Here’s 1 Stock Every Investor Should Have on Their Radar.